368 related articles for article (PubMed ID: 23613597)
1. Fast-acting fentanyl preparations and pain management.
McWilliams K; Fallon M
QJM; 2013 Oct; 106(10):887-90. PubMed ID: 23613597
[TBL] [Abstract][Full Text] [Related]
2. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
3. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Núñez-Olarte JM; Alvarez-Jiménez P
J Pain Symptom Manage; 2011 Dec; 42(6):e6-8. PubMed ID: 22048003
[No Abstract] [Full Text] [Related]
4. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
5. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
6. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
9. Fentanyl pectin nasal spray for breakthrough cancer pain.
Taylor DR; Gabrail N
Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
[TBL] [Abstract][Full Text] [Related]
10. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
11. Use of oral formulations of fentanyl for breakthrough cancer pain.
Handsaker S; Dempsey L; Fabby C
Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
[No Abstract] [Full Text] [Related]
12. The management of wound-related procedural pain (volitional incident pain) in advanced illness.
Gallagher R
Curr Opin Support Palliat Care; 2013 Mar; 7(1):80-5. PubMed ID: 23150425
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
14. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
15. [Management of breakthrough cancer pain].
Sláma O
Klin Onkol; 2013; 26(3):191-4. PubMed ID: 23763322
[TBL] [Abstract][Full Text] [Related]
16. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
18. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
[TBL] [Abstract][Full Text] [Related]
19. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl buccal tablet for breakthrough cancer pain: why titrate?
Kleeberg UR; Filbet M; Zeppetella G
Pain Pract; 2011; 11(2):185-90. PubMed ID: 20807349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
